Skip to main content
Have a personal or library account? Click to login
Circulating miR-29 and miR-320 as biomarkers of clinical compensation in ischaemic and non-ischaemic dilated cardiomyopathy Cover

Circulating miR-29 and miR-320 as biomarkers of clinical compensation in ischaemic and non-ischaemic dilated cardiomyopathy

Open Access
|Jun 2026

References

  1. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. Circulation. 2022;145(18):e895–1032. doi: 10.1161/CIR.0000000000001063
  2. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):359–3726. doi: 10.1093/eurheartj/ehab368
  3. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA. 2002;287(5):628–640. doi: 10.1001/jama.287.5.628
  4. Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol. 2020;76:400–412. doi: 10.1016/j.jacc.2020.05.041
  5. Hamsho K, Broadwin M, Stone CR, Sellke FW, Abid MR. The current state of extracellular matrix therapy for ischemic heart disease. Med Sci (Basel). 2024;12(1):8. doi: 10.3390/medsci12010008
  6. Frangogiannis NG. The extracellular matrix in ischemic and nonischemic heart failure. Circ Res. 2019;125(1):117–146. doi: 10.1161/CIRCRESAHA.119.311148
  7. Pavlović N, Todorović P, Maglica M, Kumrić M, Vukojević K, Pogorelić Z, et al. Mitochondrial dysfunction in cardiomyopathy and heart failure: from energetic collapse to therapeutic opportunity. Biomolecules. 2025;15(11):1572. doi: 10.3390/biom15111572
  8. Greenwell AA, Gopal K, Ussher JR. Myocardial energy metabolism in non-ischemic cardiomyopathy. Front Physiol. 2020;16(11):570421. doi: 10.3389/fphys.2020.57042
  9. Vavassori C, Cipriani E, Colombo GI. Circulating microRNAs as novel biomarkers in risk assessment and prognosis of coronary artery disease. Eur Cardiol Rev. 2022;17:e06. doi: 10.15420/ecr.2021.47
  10. D’Amato A, Prosperi S, Severino P, Myftari V, Correale M, Perrone Filardi P, et al. MicroRNA and heart failure: a novel promising biomarker to aid in diagnosis and prognosis. J Clin Med. 2024;13(24):7560. doi: 10.3390/jcm13247560
  11. Tan J, Tong BD, Wu YJ, Xiong W. MicroRNA-29 mediates TGFβ1-induced extracellular matrix synthesis by targeting wnt/β-catenin pathway in human orbital fibroblasts. Int J Clin Exp Pathol. 2014;7(11):7571–7577.
  12. He Y, Huang C, Lin X, Li J. MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases. Biochimie. 2013;95:1355–1359. doi: 10.1016/j. biochi.2013.03.010
  13. Horita M, Farquharson C, Stephen LA. The role of miR-29 family in disease. J Cell Biochem. 2021;122(7):696–715. doi: 10.1002/jcb.29896
  14. Liu Y, Afzal J, Vakrou S, Greenland GV, Talbot CC Jr, Hebl VB, et al. Differences in microRNA-29 and pro-fibrotic gene expression in mouse and human hypertrophic cardiomyopathy. Front Cardiovasc Med. 2019;6:170. doi: 10.3389/fcvm.2019.00170
  15. Zhang X, McLendon JM, Peck BD, Chen B, Song LS, Boudreau RL. Modulation of miR-29 influences myocardial compliance likely through coordinated regulation of calcium handling and extracellular matrix. Mol Ther Nucleic Acids. 2023;34:102081. doi: 10.1016/j.omtn.2023.102081
  16. Du H, Zhao Y, Yin Z, Wang DW, Chen C. The role of miR-320 in glucose and lipid metabolism disorder-associated diseases. Int J Biol Sci. 2021;17(2):402–416. doi: 10.7150/ijbs.53419
  17. Vezza T, de Marañón AM, Canet F, Díaz-Pozo P, Marti M, D’Ocon P, et al. MicroRNAs and oxidative stress: an intriguing crosstalk to be exploited in the management of type 2 diabetes. Antioxidants (Basel). 2021;10(5):802. doi: 10.3390/antiox10050802
  18. Włodarski A, Strycharz J, Wróblewski A, Kasznicki J, Drzewoski J, Śliwińska A. The role of microRNAs in metabolic syndrome-related oxidative stress. Int J Mol Sci. 2020;21(18):6902. doi: 10.3390/ijms21186902
  19. Li H, Fan J, Zhao Y, Zhang X, Dai B, Zhan J, et al. Nuclear miR-320 mediates diabetes-induced cardiac dysfunction by activating transcription of fatty acid metabolic genes to cause lipotoxicity in the heart. Circ Res. 2019;125(12):1106–1120. doi: 10.1161/CIRCRESAHA.119.314898
  20. Tashkandi AJ, Gorman A, McGoldrick Mathers E, Carney G, Yacoub A, Setyaningsih WAW, et al. Metabolic and mitochondrial dysregulations in diabetic cardiac complications. Int J Mol Sci. 2025;26(7):3016. doi: 10.3390/ijms26073016
  21. Peterlin A, Počivavšek K, Petrovič D, Peterlin B. The role of microRNAs in heart failure: a systematic review. Front Cardiovasc Med. 2020;7:161. doi: 10.3389/fcvm.2020.00161
  22. Zhang L, Zhang G, Lu Y, Gao J, Qin Z, Xu S, et al. Differential expression profiles of plasma exosomal microRNAs in dilated cardiomyopathy with chronic heart failure. J Cell Mol Med. 2023;27:1988–2003. doi: 10.1111/jcmm.17789
  23. Wang H, Cai J. The role of microRNAs in heart failure. Biochim Biophys Acta Mol Basis Dis. 2017;1863(8):2019–2030. doi: 10.1016/j. bbadis.2016.11.034
  24. Peltier HJ, Latham GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA. 2008;14(5):844–852. doi: 10.1261/rna.939908
  25. Schmittgen TD, Livak KJ. Comparative C(T) method for qPCR. Nat Protoc. 2008;3:1101–1108. doi: 10.1038/nprot.2008.73
  26. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55(4):611–622. doi: 10.1373/clinchem.2008.112797
  27. Aldweib N, Elia EG, Brainard SB, Wu F, Sleeper LA, Rodriquez C, et al. Serial cardiac biomarker assessment in adults with congenital heart disease hospitalized for decompensated heart failure. Int J Cardiol Congenit Heart Dis. 2022;7:100336. doi: 10.1016/j.ijcchd.2022.100336
  28. Wang M, Huo Z, He X, Liu F, Liang J, Wu L, et al. The role of miR-29 in the mechanism of fibrosis. Mini Rev Med Chem. 2023;23(19):1846–1858. doi: 10.2174/1389557523666230328125031
  29. Kwon JJ, Factora TD, Dey S, Kota JA. Systematic review of miR-29 in cancer. Mol Ther Oncolytics. 2018;12:173–194. doi: 10.1016/j. omto.2018.12.011
  30. Travers JG, Kamal FA, Robbins J, Yutzey KE, Blaxall BC. Cardiac fibrosis: the fibroblast awakens. Circ Res. 2016;118(6):1021–1040. doi: 10.1161/CIRCRESAHA.115.306565
  31. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007;87(4):1285–1342. doi: 10.1152/physrev.00012.2007
  32. Xue Y, Fan X, Yang R, Jiao Y, Li Y. miR-29b-3p inhibits post-infarct cardiac fibrosis by targeting FOS. Biosci Rep. 2020;40(9):BSR20201227. doi: 10.1042/BSR20201227
  33. Li H, Fan J, Chen C, Wang DW. Subcellular microRNAs in diabetic cardiomyopathy. Ann Transl Med. 2020;8(23):1602. doi: 10.21037/atm-20-2205
  34. Guo R, Nair S. Role of microRNA in diabetic cardiomyopathy: from mechanism to intervention. Biochim Biophys Acta Mol Basis Dis. 2017;1863(8):2070–2077. doi: 10.1016/j.bbadis.2017.03.013
  35. De A, Sarkar A, Banerjee T, Bhowmik R, Sar S, Shaharyar MA, et al. MicroRNA: unveiling novel mechanistic and theranostic pathways in diabetic cardiomyopathy. Front Pharmacol. 2025;16:1613844. doi: 10.3389/fphar.2025.1613844
  36. Mueller-Hennessen M, Sigl J, Fuhrmann JC, Witt H, Reszka R, Schmitz O, et al. Metabolic profiles in heart failure due to non-ischemic cardiomyopathy at rest and under exercise. ESC Heart Fail. 2017;4(2):178–189. doi: 10.1002/ehf2.12133
  37. Manzi L, Buongiorno F, Narciso V, Florimonte D, Forzano I, Castiello DS, et al. Acute heart failure and non-ischemic cardiomyopathies: a comprehensive review and critical appraisal. Diagnostics (Basel). 2025;15(5):540. doi: 10.3390/diagnostics15050540
  38. Profire BŞ, Lupaşcu FG, Stătescu C, Şorodoc V, Sascău RA, Profire L, et al. Heart failure biomarkers-pathophysiology, diagnosis, prognosis and clinical relevance. Int J Mol Sci. 2025;26(19):9740. doi: 10.3390/ijms26199740
  39. Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol. 2017;14(1):30–38. doi: 10.1038/nrcardio.2016.163
DOI: https://doi.org/10.2478/rjc-2026-0013 | Journal eISSN: 2734-6382 | Journal ISSN: 1220-658X
Language: English
Published on: Jun 1, 2026
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2026 Mark Onsy Dimitry, Osama Louis, Solaf Ahmed Kamel, Eman Mahmoud Hassan, Rasha Nazih, Sally M. Hafez, Amira N. Ahmed, Amira Fawzy Soliman, Eman Awadallah, published by Romanian Society of Cardiology
This work is licensed under the Creative Commons Attribution 4.0 License.

AHEAD OF PRINT